Our Company

Ikaria is a biotherapeutics company whose innovative therapeutics and interventions address the significant unmet needs of critically ill patients. Our deep understanding of the biology of critical conditions, insight into the clinical picture of critically ill patients, and working knowledge of the needs of critical care providers fuel our efforts. We strive to provide the advanced therapies and clinical support caregivers need to intervene in the most urgent situations.

Download a PDF of the Ikaria corporate brochure

Mission

At Ikaria, our mission is to significantly improve the lives of critically ill patients every single day through:

  • Our innovative therapies that directly influence patient outcomes and provide hope to families
  • Our dedication to the healthcare professionals who provide care when it is most critical
  • Our value of the diverse talents, energy, and pride of all of our employees
  • The integration of our scientific, clinical, and caregiver expertise
  • Our foundation, which is built on integrity and unwavering quality standards

Heritage

A big dream. An even bigger frontier where anything is possible.

References

  1. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci. 2009;14:1-18.
  2. Westphal M, Rehberg S, Ertmer C, Morelli A. Terlipressin -- more than just a prodrug of lysine vasopressin? Crit Care Med. 2009;37(3):1135-1136.
  3. Landa N, Miller L, Feinberg MS, et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation. 2008;117(11):1388-1396.

Capabilities

We are fully integrated and fully dedicated

Our competencies run deep: from our strong in-house R&D to our sales & marketing.

Learn more about our areas of expertise by clicking on each capability.

References

  1. Blakemore C, Jennett S. Nitric oxide. Encyclopedia.com Web site. http://www.encyclopedia.com/printable.aspx?id=10128.nitricoxide. Accessed May 27, 2009.
  2. INOMAX® Australian Approved Product Information.
  3. Lee DC, Ferguson KL. Methemoglobinemia. eMedicine Web site. http://emedicine.medscape.com/article/815613-overview. Accessed May 29, 2009.
  4. Kuhl SJ, Rosen H. Nitric oxide and septic shock: from bench to bedside. West J Med. 1998;168(3):176–181.  
  5. Westphal M, Rehberg S, Ertmer C, Morelli A. Terlipressin -- more than just a prodrug of lysine vasopressin? Crit Care Med. 2009;37(3):1135-1136.
  6. Landa N, Miller L, Feinberg MS, et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation. 2008;117(11):1388-1396.